Myocardial InfarctionNCT04131816
HeartHome: A Nurse-Driven, Home-Based Cardiac Rehabilitation Program
A study testing HeartHome in people with Myocardial Infarction and Acute Coronary Syndrome, run by University of North Carolina, Chapel Hill at 1 site in United States.
Trial summary
The purpose of this implementation trial is to execute a nurse-led, home-based cardiac rehabilitation (HBCR) program, evaluate the program's impact on patient outcomes over 6 months; and compare outcomes of HeartHome (HH) participants to a group of participants in traditional cardiac rehabilitation (CR). Read more about this study
- Who is it for?
- Ages 40 to 80 years
- Conditions the study is for
- Myocardial Infarction, Acute Coronary Syndrome, ST-segment Elevation Myocardial Infarction (STEMI)
- What is being tested?
- HeartHome
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 14 participants
- Where
- 1 siteUnited States
- Study dates
- 10 Nov 2019to 11 Feb 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Individuals are eligible for the HeartHome study if they meet all the following inclusion criteria:
- Diagnosed with one of the following conditions: myocardial infarction (MI)/acute coronary syndrome (ACS), ST-elevation myocardial infarction (STEMI), non-STEMI, percutaneous coronary intervention (PCI) or stable angina;
- Decline traditional cardiac rehab or do not respond to traditional cardiac rehab enrollment methods;
- Willing to have a nurse visit them in their home and receive follow-up phone calls and text messages for a 12-week intervention period;
- Understand the requirements of participation in and consent to the HeartHome program;
- Live within a 75-mile radius of the study site.
Individuals are not eligible for the HeartHome study if they meet any of the following exclusion criteria:
- Diagnosis of heart failure
- Diagnosis of valvular heart disease
- Presence of cardiac disease requiring surgery or other invasive procedure
- Impaired mental capacity resulting in an inability to understand or follow directions and study protocol
- Impaired functional abilities that prevent them from participating in physical activity
- Presence of any serious medical conditions that are likely to cause premature death or to impair functional capacity
- No access to a telephone
Trial locations and contacts
1 site in 1 country.
About this study
The purpose of this implementation trial is to execute a nurse-led, home-based cardiac rehabilitation (HBCR) program, evaluate the program's impact on patient outcomes over 6 months; and compare outcomes of HeartHome (HH) participants to a group of participants in traditional cardiac rehabilitation (CR).
Read the detailed description
Despite being recognized as a class 1 recommendation by the American Heart Association (AHA), traditional CR is underused: only 20% of patients who need CR are referred, and only half of those referred enroll in the program. The primary barriers to enrollment in CR include the failure of providers to refer patients; systems that lack a clear, streamlined referral process; and patients who face multiple barriers, including knowledge, transportation, cost, time, and social-family support.
The HeartHome program is adapted from MULTIFIT, an evidence-based, interdisciplinary model of care developed at Stanford University was originally designed to provide coronary risk factor modification in post-MI patients, and later modified to implement consensus guidelines for providing HBCR to individuals with CVD using nurse managed care via telephone follow-up. HeartHome will combine nurse home visits with telephone and electronic supports for participants in a HBCR program that allows them to engage in cardiac rehabilitation programs at home.
In this trial, nurses will deliver the 12-week educational program to 150 participants. Participants will then complete follow-up assessments at the end of the program (3 months post enrollment), and then at 6-months post enrollment. The data collected will be compared to a control group that contains de-identified data from 150 patients that attend the traditional cardiac rehab program.
- Conditions
- Myocardial Infarction, Acute Coronary Syndrome, ST-segment Elevation Myocardial Infarction (STEMI), Non-ST-Segment Elevation Myocardial Infarction (NSTEMI), Angina, Stable
- Being tested
- HeartHome
- Keywords
- Cardiac Rehabilitation
- Medical subject headings
- Myocardial Infarction, Acute Coronary Syndrome, ST Elevation Myocardial Infarction, Non-ST Elevated Myocardial Infarction, Angina, Stable
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
HeartHomeBehavioural
The HeartHome program is an expanded home-based cardiac rehabilitation program that combines nurse home visits with telephone and electronic supports for participants that allows them to engage in cardiac rehabilitation activities at home.
| Study group | Role | What they receive |
|---|---|---|
| HeartHome Intervention | Experimental | Participants will be in the HeartHome program for a total of 12 weeks. Receives: Behavioral: HeartHome |
| Control | No intervention | De-identified data from 150 patients who attend a traditional cardiac rehabilitation program during the same general time of the HeartHome implementation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of HeartHome patient referrals into the HeartHome program
Number of patient referrals into the HeartHome program will be measured by the total number of participants eligible to enroll in traditional cardiac rehab that were referred to the HeartHome program.
Measured: 10 months after beginning of study
Proportion of HeartHome patient referral into the HeartHome program
Proportion of patient referrals into the HeartHome program will be measured by the number of patients referred to the HeartHome program relative to the number of patients referred to traditional cardiac rehab.
Measured: 10 months after beginning of study
Proportion of HeartHome patient enrollments in the HeartHome program
Proportion of patient enrollments in the HeartHome program will be measured by the number of patients who enroll in the HeartHome program relative to the number of eligible patients referred to the HeartHome program. Enrollment is defined by signing the study consent form.
Measured: 10 months after beginning of study
Participation in HeartHome's participants in-person visits
Participation in HeartHome's in-person visits will be measured by the number of in-person visits that each participant attends relative to the total number of in-person visits. The total number of visits possible per person is 5, with higher numbers associated with better participation.
Measured: 12 weeks post HeartHome intervention start
Participation in HeartHome's participants interactive online classes
Participation in HeartHome's online classes will be measured by the number of online classes that each participant attends relative to the total number of interactive online classes. The total number of classes possible is 7, with higher numbers associated with better participation.
Measured: 12 weeks post HeartHome intervention start
Participation in HeartHome intervention calls
Participation in HeartHome's calls will be measured by the number of calls that each participant attends relative to the total number of calls. The total number of calls possible is 8, with higher rate associated with better participation.
Measured: 12 weeks post HeartHome intervention start
HeartHome intervention weekly goal adherence score
Adherence to weekly goals will be measured by participant goal achievement, which includes 33 opportunities for goal achievement and progression. The range is 0-33, with higher scores associated with greater adherence to weekly goals.
Measured: 12 weeks post HeartHome intervention start
Number of sessions completed.
Sessions completed by participants will be measured by the total number of calls, interactive online classes, and in-person visits attended. The total number of sessions is 20, with higher numbers associated with higher participation. Sessions completed by the control group will be measured by the total number of exercise sessions and classes attended. The total number of sessions for the control group is 46, with higher numbers associated with higher participation.
Measured: 13-weeks post start of HeartHome and control intervention
Secondary outcomes (33)
HeartHome participants' physical function at baseline and at week 12
HeartHome participants' physical function will be measured by the six-minute walk distances at baseline and at 12 weeks. Longer distances (in meters) are associated with higher physical function.
Measured: 12 weeks post start of HeartHome intervention
Change in HeartHome participant's physical functioning, sub score of RAND SF-36 from baseline to week 12 and baseline to week 24.
Change in participants' physical function will be measured by a sub score of the RAND Short Form Survey Instrument (SF-36). The range is 0 - 100, and higher scores are associated with better physical function.
Measured: 12- and 24-weeks post start of intervention
Change in HeartHome participant's role limitations due to physical health, sub score of RAND SF-36 from baseline to week 12 and baseline to week 24.
Change in participants' role limitations due to physical health will be measured by a sub score of the RAND Short Form Survey Instrument (SF-36). The range is 0 - 100, and higher scores are associated with fewer role limitations due to physical health.
Measured: 12- and 24- weeks post start of intervention
Change in HeartHome participant's role limitations due to emotional problems, sub score of RAND SF-36 from baseline to week 12 and baseline to week 24.
Change in participants' role limitations due to emotional problems will be measured by a sub score of the RAND Short Form Survey Instrument (SF-36). The range is 0 - 100, and higher scores are associated with fewer role limitations due to emotional problems.
Measured: 12- and 24- weeks post start of intervention
Change in HeartHome participant's energy/fatigue, sub score of RAND SF-36 from baseline to week 12 and baseline to week 24.
Change in participants' energy/fatigue will be measured by a sub score of the RAND Short Form Survey Instrument (SF-36). The range is 0 - 100, and higher scores are associated with higher energy/lower fatigue.
Measured: 12- and 24- weeks post start of intervention
HeartHome participant's emotional well-being, sub score of RAND SF-36, assessed at baseline, week 12, and week 24.
Participants' emotional well-being will be measured by a sub score of the RAND Short Form Survey Instrument (SF-36). The range is 0 - 100, and higher scores are associated with better emotional well-being.
Measured: 12- and 24-weeks post start of intervention
HeartHome participant's social functioning, sub score of RAND SF-36, evaluated at baseline, week 12, and week 24.
Participants' social functioning will be measured by a sub score of the RAND Short Form Survey Instrument (SF-36). The range is 0 - 100, and higher scores are associated with better social functioning.
Measured: 12- and 24-weeks post start of intervention
HeartHome participant's bodily pain, a sub score of RAND SF-36, will be evaluated at baseline, week 12 and week 24.
Participants' bodily pain will be measured by a sub score of the RAND Short Form Survey Instrument (SF-36). The range is 0 - 100, and higher scores are associated with less pain.
Measured: 12- and 24- weeks post start of intervention
HeartHome participant's general health, sub score of RAND SF-36 at baseline, week 12, and week 24.
Participants' general health will be measured by a sub score of the RAND Short Form Survey Instrument (SF-36). The range is 0 - 100, and higher scores are associated with better general health.
Measured: 12- and 24-weeks post start of intervention
HeartHome participant's change of participant and control physical functioning, sub score of RAND SF-36, from baseline to week 12 to end of program
Participants' physical function will be measured by a sub score of the RAND SF-36. The range is 0-100, and higher scores are associated with better physical functioning.
Measured: 13-weeks post start of HeartHome and control intervention
HeartHome participant's blood pressure at baseline and weeks 3, 5, 7 and 12.
Blood pressure will be measured by blood pressure measurements, measured in mmHg.
Measured: Baseline, weeks 3, 5, 7, and 12 of intervention
Participants' and control's blood pressure at baseline and 12 weeks
Blood pressure will be measured by blood pressure measurements, measured in mmHg.
Measured: Baseline and 13-weeks post start of HeartHome and control intervention
Change in HeartHome participant's reported nicotine use from baseline to week 12 and baseline to week 24.
Rates of nicotine use will be measured by the change in participant-reported number of cigarettes smoked per week and patient-report of weekly frequency of non-cigarette nicotine use from baseline to week 12, and baseline to week 24.
Measured: 12- and 24-weeks post start of intervention
HeartHome participant's waist circumference from baseline to week 12.
Waist circumference will be measured in centimeters at the beginning of the intervention (HeartHome program) and 12 weeks after beginning the intervention (HeartHome program). Negative changes in waist circumference are associated with greater weight loss.
Measured: 12 weeks post start of intervention
HeartHome participant's Body Mass Index at baseline and week 12.
Body Mass Index will be calculated from the participants' weights and heights at the beginning of the intervention (HeartHome program) and 12 weeks after beginning the intervention (HeartHome program). Lower numbers are associated with weight loss, and a patients' healthy range varies by age and gender.
Measured: Baseline and 12 weeks post start of intervention
Change of HeartHome participants' and control Body Mass Index from baseline to week 12
Body Mass Index will be calculated by assessing participant weight and height at the beginning of the intervention (HeartHome program) and 12 weeks after beginning the intervention (HeartHome Program). Lower numbers are associated with weight loss, and a patients' healthy range varies by age and gender.
Measured: Baseline and 13-weeks post start of HeartHome and control intervention
HeartHome participant's average weekly steps walked from baseline to week 12.
Average steps walked will be calculated using electronic fitness trackers at the beginning of the intervention (HeartHome program) and 12 weeks after beginning the intervention (HeartHome program). Higher numbers are associated with higher physical activity.
Measured: 12 weeks post start of intervention
HeartHome participant's self-Reported and medical record reviewed number of hospital admissions 12 and 24 weeks after beginning of heart home program.
Participants' days of care utilization will be measured using the self-reported and medical record reviewed number of instances the participant is hospitalized in 12 and 24 weeks after the beginning of the heart home program.
Measured: 12- and 24- weeks post start of intervention
HeartHome participant's self-Reported and medical record reviewed number of days hospitalized 12 and 24 weeks after beginning of heart home program.
Participants' days of care utilization will be measured using the self-reported and medical record reviewed number of combined days the participant spends in the hospital in 12 and 24 weeks after the beginning of the heart home program.
Measured: 12- and 24- weeks post start of intervention
HeartHome participant and control number of hospital readmissions at 12 weeks
Hospital readmission will be measured using patient self-reports and medical record reviews of hospital admissions (yes/no) at 12 weeks after the start of the intervention (HeartHome program).
Measured: 13-weeks post start of HeartHome and control intervention
HeartHome participant's self-reported and medical record reviewed number of ED visits without hospital admissions 12 and 24 weeks after beginning of HeartHome program
Participants' days of care utilization will be measured using the self-reported and medical record reviewed number of combined visits the participant makes to the Emergency Department (ED) in 12 and 24 weeks after the beginning of the heart home program.
Measured: 12- and 24- weeks post start of intervention
HeartHome participant's self-reported and medical record reviewed number of specialist visits 12 and 24 weeks after beginning of the HeartHome program
Participants' number of specialist visits will be measured using self-reported and medical record reviewed number of combined cardiology visits 12 and 24 weeks after the beginning of the heart home program.
Measured: 12- and 24- weeks post start of intervention
HeartHome participant's self-reported and medical record reviewed number of primary care visits 12 and 24 weeks after beginning of the HeartHome program
Participants' number of primary care visits will be measured using self-reported and medical record reviewed number of combined primary care visits 12 and 24 weeks after the beginning of the heart home program.
Measured: 12- and 24- weeks post start of intervention
HeartHome participant's self-reported and medical record reviewed number of urgent care visits 12 and 24 weeks after beginning of the HeartHome program
Participants' number of urgent care visits will be measured using self-reported and medical record reviewed number of combined urgent care visits 12 and 24 weeks after the beginning of the heart home program.
Measured: 12- and 24- weeks post start of intervention
HeartHome participant's Morisky 4-Item Scale scores at baseline, week 12, and week 24.
Management of participants' medications will be measured using the Morisky 4-item scale, which includes four questions to estimate the risk of medication non-adherence. The range is 0 to 4, and lower scores are associated with lower levels of medication adherence.
Measured: 12- and 24-weeks post start of intervention
HeartHome participant's change in perceived stress scale from baseline to week 12 and baseline to week 24.
Participants' stress and emotional state will be measured using the perceived stress scale, which includes ten questions about individuals' feelings and thoughts during the last month. The range is 0-40, and higher scores are associated with higher levels of perceived stress.
Measured: 12 and 24 weeks post start of intervention
HeartHome participant's change in dietary risk assessment from baseline to week 12 and baseline to week 24.
Participants' diet and lifestyle change will be measured by the dietary risk assessment, which includes 33 questions about how many servings of commonly eaten foods that participants eat in a usual day or an average week. The range is 0-52, higher scores represent a more healthful dietary pattern.
Measured: 12- and 24- weeks post start of intervention
Participants' and control's dietary risk assessment scores from baseline to week 12 to dietary risk assessment scores of control group.
Participants' diet and lifestyle change will be measured by the dietary risk assessment, which includes 33 questions about how many servings of commonly eaten foods that participants eat in a usual day or an average week. The range is 0-52, higher scores represent a more healthful dietary pattern.
Measured: 13-weeks post start of HeartHome and control intervention
HeartHome participant's change in PHQ-9 from baseline to week 12.
Participants' emotional state will be measured by the Patient Health Questionnaire (PHQ)-9, which includes 9 questions for screening, diagnosing, monitoring, and measuring the severity of depression. The range is 0 to 27, and scores represent cut-points for mild to severe levels of depression.
Measured: 12 weeks post start of intervention
Change in participants' and control's PHQ-9 from baseline to week 12.
Participants' emotional state will be measured by the PHQ-9, which includes 9 questions for screening, diagnosing, monitoring, and measuring the severity of depression. The range is 0 to 27, and scores represent cut-points for mild to severe levels of depression, with higher scores associated with more severe levels of depression.
Measured: 13-weeks post start of HeartHome and control intervention
HeartHome participant's change in New General Self-Efficacy score from baseline to week 12 and baseline to week 24.
Participants' confidence regarding task and situational performance is measured by the New General Self-Efficacy Scale, which includes 8 questions about participant confidence. The range is 8 to 40, and higher scores are associated with higher self-efficacy.
Measured: 12- and 24-weeks post start of intervention
HeartHome participant's change in knowledge of cardiac rehabilitation from baseline to 12 weeks and baseline to 24 weeks.
Participants' knowledge of cardiac rehabilitation is measured by a 10-item Cardiac Rehabilitation Knowledge test at baseline, 12 weeks and 24 weeks. Scores range from 0-10, with higher scores associated with greater knowledge of cardiac rehabilitation.
Measured: 12- and 24-weeks post start of intervention
Participants' and control's change in knowledge of cardiac rehabilitation from baseline to 12 weeks.
Participants' knowledge of cardiac rehabilitation is measured by a 10-item Cardiac Rehabilitation Knowledge test at baseline, 12 weeks and 24 weeks. Scores range from 0-10, with higher scores associated with greater knowledge of cardiac rehabilitation.
Measured: 13-weeks post start of HeartHome and control intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Oct 2019
- Study start10 Nov 2019
- Primary completion11 Feb 2022
- Study completion11 Feb 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Myocardial InfarctionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 14 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of North Carolina, Chapel Hill
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Cheryl Jones, PhD, RN, Principal investigator, University of North Carolina, Chapel Hill
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04131816
- Sponsor's protocol ID
- 18-2540
- Status last verified
- Mar 2022
- First submitted
- 16 Oct 2019
- Last updated
- 4 Apr 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 4 Apr 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- HeartHome: A Nurse-Driven, Home-Based Cardiac Rehabilitation Program
- ClinicalTrials.gov ID
- NCT04131816
- Acronym / sponsor ID
- 18-2540
- Conditions
- Myocardial Infarction, Acute Coronary Syndrome, ST-segment Elevation Myocardial Infarction (STEMI), Non-ST-Segment Elevation Myocardial Infarction (NSTEMI), Angina, Stable
- Keywords
- Cardiac Rehabilitation
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 14 participants (actual)
- Lead sponsor
- University of North Carolina, Chapel HillUniversity, hospital or other
- Study start
- 10 Nov 2019 (actual)
- Primary completion
- 11 Feb 2022 (actual)
- Study completion
- 11 Feb 2022 (actual)
- First posted
- 18 Oct 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this implementation trial is to execute a nurse-led, home-based cardiac rehabilitation (HBCR) program, evaluate the program's impact on patient outcomes over 6 months; and compare outcomes of HeartHome (HH) participants to a group of participants in traditional cardiac rehabilitation (CR).
Detailed description
Despite being recognized as a class 1 recommendation by the American Heart Association (AHA), traditional CR is underused: only 20% of patients who need CR are referred, and only half of those referred enroll in the program. The primary barriers to enrollment in CR include the failure of providers to refer patients; systems that lack a clear, streamlined referral process; and patients who face multiple barriers, including knowledge, transportation, cost, time, and social-family support.
The HeartHome program is adapted from MULTIFIT, an evidence-based, interdisciplinary model of care developed at Stanford University was originally designed to provide coronary risk factor modification in post-MI patients, and later modified to implement consensus guidelines for providing HBCR to individuals with CVD using nurse managed care via telephone follow-up. HeartHome will combine nurse home visits with telephone and electronic supports for participants in a HBCR program that allows them to engage in cardiac rehabilitation programs at home.
In this trial, nurses will deliver the 12-week educational program to 150 participants. Participants will then complete follow-up assessments at the end of the program (3 months post enrollment), and then at 6-months post enrollment. The data collected will be compared to a control group that contains de-identified data from 150 patients that attend the traditional cardiac rehab program.
Study design
- Primary purpose
- Supportive care
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| HeartHome Intervention | Experimental | Behavioral: HeartHomeParticipants will be in the HeartHome program for a total of 12 weeks. |
| Control | No intervention | –De-identified data from 150 patients who attend a traditional cardiac rehabilitation program during the same general time of the HeartHome implementation |
Who may qualify
- Ages
- 40 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| HeartHomeThe HeartHome program is an expanded home-based cardiac rehabilitation program that combines nurse home visits with telephone and electronic supports for participants that allows them to engage in cardiac rehabilitation activities at home. | Behavioural | HeartHome Intervention |
Primary outcome
Number of HeartHome patient referrals into the HeartHome program
Time frame: 10 months after beginning of study
Number of patient referrals into the HeartHome program will be measured by the total number of participants eligible to enroll in traditional cardiac rehab that were referred to the HeartHome program.
Proportion of HeartHome patient referral into the HeartHome program
Time frame: 10 months after beginning of study
Proportion of patient referrals into the HeartHome program will be measured by the number of patients referred to the HeartHome program relative to the number of patients referred to traditional cardiac rehab.
Proportion of HeartHome patient enrollments in the HeartHome program
Time frame: 10 months after beginning of study
Proportion of patient enrollments in the HeartHome program will be measured by the number of patients who enroll in the HeartHome program relative to the number of eligible patients referred to the HeartHome program. Enrollment is defined by signing the study consent form.
Participation in HeartHome's participants in-person visits
Time frame: 12 weeks post HeartHome intervention start
Participation in HeartHome's in-person visits will be measured by the number of in-person visits that each participant attends relative to the total number of in-person visits. The total number of visits possible per person is 5, with higher numbers associated with better participation.
Participation in HeartHome's participants interactive online classes
Time frame: 12 weeks post HeartHome intervention start
Participation in HeartHome's online classes will be measured by the number of online classes that each participant attends relative to the total number of interactive online classes. The total number of classes possible is 7, with higher numbers associated with better participation.
Participation in HeartHome intervention calls
Time frame: 12 weeks post HeartHome intervention start
Participation in HeartHome's calls will be measured by the number of calls that each participant attends relative to the total number of calls. The total number of calls possible is 8, with higher rate associated with better participation.
HeartHome intervention weekly goal adherence score
Time frame: 12 weeks post HeartHome intervention start
Adherence to weekly goals will be measured by participant goal achievement, which includes 33 opportunities for goal achievement and progression. The range is 0-33, with higher scores associated with greater adherence to weekly goals.
Number of sessions completed.
Time frame: 13-weeks post start of HeartHome and control intervention
Sessions completed by participants will be measured by the total number of calls, interactive online classes, and in-person visits attended. The total number of sessions is 20, with higher numbers associated with higher participation. Sessions completed by the control group will be measured by the total number of exercise sessions and classes attended. The total number of sessions for the control group is 46, with higher numbers associated with higher participation.
33 secondary outcomes
HeartHome participants' physical function at baseline and at week 12
Time frame: 12 weeks post start of HeartHome intervention
Change in HeartHome participant's physical functioning, sub score of RAND SF-36 from baseline to week 12 and baseline to week 24.
Time frame: 12- and 24-weeks post start of intervention
Change in HeartHome participant's role limitations due to physical health, sub score of RAND SF-36 from baseline to week 12 and baseline to week 24.
Time frame: 12- and 24- weeks post start of intervention
Change in HeartHome participant's role limitations due to emotional problems, sub score of RAND SF-36 from baseline to week 12 and baseline to week 24.
Time frame: 12- and 24- weeks post start of intervention
Change in HeartHome participant's energy/fatigue, sub score of RAND SF-36 from baseline to week 12 and baseline to week 24.
Time frame: 12- and 24- weeks post start of intervention
HeartHome participant's emotional well-being, sub score of RAND SF-36, assessed at baseline, week 12, and week 24.
Time frame: 12- and 24-weeks post start of intervention
HeartHome participant's social functioning, sub score of RAND SF-36, evaluated at baseline, week 12, and week 24.
Time frame: 12- and 24-weeks post start of intervention
HeartHome participant's bodily pain, a sub score of RAND SF-36, will be evaluated at baseline, week 12 and week 24.
Time frame: 12- and 24- weeks post start of intervention
HeartHome participant's general health, sub score of RAND SF-36 at baseline, week 12, and week 24.
Time frame: 12- and 24-weeks post start of intervention
HeartHome participant's change of participant and control physical functioning, sub score of RAND SF-36, from baseline to week 12 to end of program
Time frame: 13-weeks post start of HeartHome and control intervention
HeartHome participant's blood pressure at baseline and weeks 3, 5, 7 and 12.
Time frame: Baseline, weeks 3, 5, 7, and 12 of intervention
Participants' and control's blood pressure at baseline and 12 weeks
Time frame: Baseline and 13-weeks post start of HeartHome and control intervention
Change in HeartHome participant's reported nicotine use from baseline to week 12 and baseline to week 24.
Time frame: 12- and 24-weeks post start of intervention
HeartHome participant's waist circumference from baseline to week 12.
Time frame: 12 weeks post start of intervention
HeartHome participant's Body Mass Index at baseline and week 12.
Time frame: Baseline and 12 weeks post start of intervention
Change of HeartHome participants' and control Body Mass Index from baseline to week 12
Time frame: Baseline and 13-weeks post start of HeartHome and control intervention
HeartHome participant's average weekly steps walked from baseline to week 12.
Time frame: 12 weeks post start of intervention
HeartHome participant's self-Reported and medical record reviewed number of hospital admissions 12 and 24 weeks after beginning of heart home program.
Time frame: 12- and 24- weeks post start of intervention
HeartHome participant's self-Reported and medical record reviewed number of days hospitalized 12 and 24 weeks after beginning of heart home program.
Time frame: 12- and 24- weeks post start of intervention
HeartHome participant and control number of hospital readmissions at 12 weeks
Time frame: 13-weeks post start of HeartHome and control intervention
HeartHome participant's self-reported and medical record reviewed number of ED visits without hospital admissions 12 and 24 weeks after beginning of HeartHome program
Time frame: 12- and 24- weeks post start of intervention
HeartHome participant's self-reported and medical record reviewed number of specialist visits 12 and 24 weeks after beginning of the HeartHome program
Time frame: 12- and 24- weeks post start of intervention
HeartHome participant's self-reported and medical record reviewed number of primary care visits 12 and 24 weeks after beginning of the HeartHome program
Time frame: 12- and 24- weeks post start of intervention
HeartHome participant's self-reported and medical record reviewed number of urgent care visits 12 and 24 weeks after beginning of the HeartHome program
Time frame: 12- and 24- weeks post start of intervention
HeartHome participant's Morisky 4-Item Scale scores at baseline, week 12, and week 24.
Time frame: 12- and 24-weeks post start of intervention
HeartHome participant's change in perceived stress scale from baseline to week 12 and baseline to week 24.
Time frame: 12 and 24 weeks post start of intervention
HeartHome participant's change in dietary risk assessment from baseline to week 12 and baseline to week 24.
Time frame: 12- and 24- weeks post start of intervention
Participants' and control's dietary risk assessment scores from baseline to week 12 to dietary risk assessment scores of control group.
Time frame: 13-weeks post start of HeartHome and control intervention
HeartHome participant's change in PHQ-9 from baseline to week 12.
Time frame: 12 weeks post start of intervention
Change in participants' and control's PHQ-9 from baseline to week 12.
Time frame: 13-weeks post start of HeartHome and control intervention
HeartHome participant's change in New General Self-Efficacy score from baseline to week 12 and baseline to week 24.
Time frame: 12- and 24-weeks post start of intervention
HeartHome participant's change in knowledge of cardiac rehabilitation from baseline to 12 weeks and baseline to 24 weeks.
Time frame: 12- and 24-weeks post start of intervention
Participants' and control's change in knowledge of cardiac rehabilitation from baseline to 12 weeks.
Time frame: 13-weeks post start of HeartHome and control intervention
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Apr 2022.
- Individual participant dataSharing planned: No
Related trials for Myocardial Infarction
RecruitingPhase 4
Efficacy and Safety of a Half-dose Bolus of r-SAK Prior to Primary PCI in ST-elevation Myocardial Infarction
ST Elevation Myocardial Infarction
Not yet recruitingPhase 4
Capital Offload-Shock
Hypervolemia, Cardiogenic Shock
Recruiting
ODSSEY-SCD_Identification Of Markers to preDict the rISk of Sudden Cardiac Death in Moderated LVEF in ischEmic cardiomyopathY
Myocardial Infarction (MI), Sudden Cardiac Death Due to Cardiac Arrhythmia
Recruiting
CRP Apheresis in Infarct-Related Cardiogenic Shock
Cardiogenic Shock, Acute Myocardial Infarction (AMI)
RecruitingObservational study
Breisgau PHENO-HEART MI
Myocardial Infarction, STEMI
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Cheryl Jones, PhD, RN principal investigator
University of North Carolina, Chapel Hill
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing HeartHome in people with Myocardial Infarction and Acute Coronary Syndrome, run by University of North Carolina, Chapel Hill at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 4 Apr 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of HeartHome patient referrals into the HeartHome program (time frame: 10 months after beginning of study). The study lists 8 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Apr 2022.